Skip to main content
. 2019 Jan 13;6(6):1801847. doi: 10.1002/advs.201801847

Figure 12.

Figure 12

a) Design and manufacture of lymphocyte‐programming nanoparticles. b) Nanoparticle‐programmed CAR lymphocytes can cause tumor regression with efficacies similar to adoptive T‐cell therapy. Reproduced with permission.178 Copyright 2017, Nature Publishing Group.